Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Novo Nordisk's stock has declined 66% from its 2024 high and now trades at attractive valuations compared to historical averages. While the company lost its GLP-1 weight-loss drug market lead to Eli Lilly, it is attempting a comeback through a new GLP-1 pill and a volume-driven pricing strategy. Despite significant uncertainty around its competitive position and business transition, the stock's low valuation and 3.7% dividend yield may appeal to value and dividend investors.

09/08/2026, 12:15 PM • The Motley Fool

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

Eli Lilly's GLP-1 weight-loss drugs (Mounjaro, Zepbound) currently drive nearly two-thirds of revenue, but face competition and patent expiration risks. The company is strategically acquiring smaller biotech firms across autoimmune, mental health, sleep disorders, and infectious disease spaces to diversify its pipeline and prepare for when GLP-1 drugs are no longer its primary revenue driver.

09/07/2026, 5:15 PM • The Motley Fool

2 Stocks Down 8% or More That Are Screaming Buys Right Now

The article highlights two beaten-down stocks as potential buying opportunities: Intuitive Surgical, down 34% year-to-date, is positioned to benefit from its da Vinci 5 surgical system's advanced features and expanding market; Novo Nordisk, down 8% this year, has promising GLP-1 pipeline candidates like amycretin and UBT251 that could help it regain market share in the weight-loss drug sector.

09/04/2026, 10:30 AM • The Motley Fool

Resalis Therapeutics Appoints Diana M. Røpcke as Chief Medical Officer

Resalis Therapeutics announced the appointment of Dr. Diana M. Røpcke as Chief Medical Officer to lead clinical strategy for RES-010, an antisense oligonucleotide in Phase 1b trials for obesity treatment. Dr. Røpcke brings extensive experience from Novo Nordisk in clinical drug development and cardiometabolic therapies.

09/02/2026, 5:00 AM • GlobeNewswire

NexLife Expands Flat-Rate Compounded GLP-1 Program With Microdose and Sublingual Protocols

NexLife, a physician-led telehealth platform, announced expanded compounded GLP-1 programs with flat-rate pricing that remains constant across all dose levels, ranging from $119-$169 monthly depending on medication and plan length. The service includes $377 in bundled nutrition, coaching, and provider support at no additional cost, independent batch testing, and expedited delivery.

08/31/2026, 8:32 PM • GlobeNewswire

Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?

Novo Nordisk, which pioneered GLP-1 weight-loss drugs but lost market leadership to Eli Lilly, is attempting a comeback through product innovation. The company has launched a pill version of Wegovy and partnered with Vivani Medical to develop an implant that could deliver the drug once or twice yearly, potentially revolutionizing convenience in the GLP-1 market. While Eli Lilly maintains a stronger market position and higher valuation, Novo Nordisk's continued innovation could help it regain competitive ground.

08/29/2026, 7:15 PM • The Motley Fool

2 Stocks That Could Capitalize on the GLP-1 Boom

The article highlights CVS Health and Roche as two stocks positioned to benefit from the growing GLP-1 drug market. CVS is leveraging its pharmacy network and low-cost telemedicine services to improve patient access to GLP-1 medications, while Roche is developing promising weight-loss drugs including CT-388, a dual GLP-1/GIP agonist showing strong clinical results. Both companies offer diversified business models beyond GLP-1 to mitigate risks.

08/25/2026, 3:18 PM • The Motley Fool

Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger

Eli Lilly's weight-loss pill Foundayo received U.K. approval, marking Europe's first GLP-1 oral medication authorization. The drug offers advantages over competitor Novo Nordisk's Wegovy with no food restrictions. The global obesity drug market is projected to grow from $66 billion in 2025 to $92-200 billion by 2027, presenting significant growth opportunities for multiple manufacturers.

08/14/2026, 10:30 AM • The Motley Fool

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly announced it will file for FDA approval of retatrutide, its next-generation weight-loss drug, in Q1 2027. The drug demonstrated 28.3% average weight loss over 80 weeks in phase 3 trials, outperforming competitors like Novo Nordisk's Wegovy. With strong Q2 financial results (48% revenue growth) and potential applications beyond obesity, Eli Lilly is positioned to expand its market lead.

08/07/2026, 6:30 PM • The Motley Fool

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Pfizer is developing berobenatide, a monthly injectable weight-loss drug that could compete with market leaders Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Phase 2b data shows 16% weight loss in 32 weeks with no plateau, positioning it as potentially competitive despite lower efficacy than rivals. The anti-obesity market is projected to reach $190 billion by 2035, offering significant opportunity, though Pfizer faces risks from patent cliffs, increased competition from companies like Amgen, and regulatory hurdles.

08/07/2026, 3:28 PM • The Motley Fool

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Viking Therapeutics stock fell 18.6% in July as investors focused on the company's cash burn ($96M quarterly) and potential shareholder dilution from a planned $500M equity offering, despite positive progress on its phase 3 trials for weight-loss drug VK2735. The company has sufficient cash through 2028 and expects trial results by then, maintaining long-term potential in the weight-loss drug market.

08/06/2026, 10:21 AM • The Motley Fool

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk announced that board members and executives received 74 shares each on August 5, 2026, through the company's Restricted Shares programme for the 100th Anniversary. The company also won a Dutch court injunction protecting patients from unapproved compounded semaglutide nasal spray, reinforcing patient safety and intellectual property rights. Additionally, Novo Nordisk reported adjusted operating profit of DKK 33,389 million for Q2 2026 and raised its full-year outlook.

08/06/2026, 3:18 AM • GlobeNewswire

Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray

Novo Nordisk secured a preliminary injunction from the District Court of The Hague against Ceban Ziekenhuisfarmacie B.V. for infringing its supplementary protection certificate on semaglutide by producing an unapproved nasal spray formulation. The court ordered Ceban to cease sales, remove product listings, disclose supply chain information, and reimburse legal costs. No semaglutide nasal spray has been approved by any regulatory authority.

08/05/2026, 9:42 AM • GlobeNewswire

Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031

Eli Lilly is positioned to become the first healthcare company to reach a $2 trillion market cap by 2031, requiring a 12.7% compound annual growth rate. The company's GLP-1 drug portfolio, led by tirzepatide (Mounjaro/Zepbound), is expected to drive strong revenue growth despite increasing competition. Additional growth catalysts include new product launches like Foundayo, pipeline candidates such as retatrutide, and AI-driven cost efficiencies across the organization.

08/01/2026, 4:17 PM • The Motley Fool

Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.

Eli Lilly has significantly outperformed Novo Nordisk in the booming GLP-1 obesity drug market, with Lilly commanding 60% market share compared to Novo's smaller portion of the combined 87% duopoly. While the obesity drug market is projected to grow from $66 billion in 2025 to $120 billion by 2030, Lilly's stock has surged 58% over 52 weeks, whereas Novo has plummeted 62% since July 2024. However, Novo's recent launch of a pill-form obesity drug could shift the competitive landscape.

07/31/2026, 1:30 PM • The Motley Fool